Gene therapy for HAE: how does it hold up over time?

NCT ID NCT06262399

First seen Jan 06, 2026 · Last updated May 11, 2026 · Updated 13 times

Summary

This study follows about 100 people who previously received the experimental gene therapy NTLA-2002 for hereditary angioedema (HAE). Researchers will monitor participants for long-term safety and check how well the treatment continues to prevent HAE attacks. The goal is to understand if a single dose can keep swelling episodes under control over many years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Campbelltown Hospital

    Campbelltown, New South Wales, 2560, Australia

  • Centre National de Reference - Grenoble

    Grenoble, France

  • Charite-Universitätsmedizin Berlin

    Berlin, 12203, Germany

  • Hôpital Claude Huriez

    Lille, 59037, France

  • New Zealand Clinical Research

    Auckland, New Zealand

  • University of Amsterdam Academic Medical Center

    Amsterdam, Netherlands

Conditions

Explore the condition pages connected to this study.